Structured evidence table for Niacin Cholesterol Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Niacin Cholesterol Meta-Analysis | There is growing interest in examining whether lipid-lowering treatment in diabetes is associated with cardiovascular outcomes. | 3 | Abdul Wahab Roshaida (2026) | Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes |
| Niacin Cholesterol Meta-Analysis | This review aims to provide a summary that will help navigate the extensive evidence base on cardiovascular outcomes trials of these agents. | 3 | Abdul Wahab Roshaida (2026) | Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes |
| Niacin Cholesterol Meta-Analysis | We prioritized evidence from systematic reviews, meta-analyses, randomized clinical trials (RCTs), and observational studies, with emphasis on studies reporting cardiovascular outcomes in patients with diabetes. | 3 | Abdul Wahab Roshaida (2026) | Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes |
| Niacin Cholesterol Meta-Analysis | 5 6 , 7 8 , 9 10 11 , 12 12 13 , 14 Atherosclerosis is a complex pathology that has been linked to various mechanisms in the context of diabetes. | 3 | Abdul Wahab Roshaida (2026) | Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes |
| Niacin Cholesterol Meta-Analysis | Elevated levels of Lp(a) have been identified as a well-established and genetically determined risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, and calcific aortic valve stenosis. | 4 | Domański I (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. |
| Niacin Cholesterol Meta-Analysis | Furthermore, the current status of clinical guidelines and the evolving role of Lp(a)-targeted therapies in cardiovascular risk stratification are reviewed. | 4 | Domański I (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. |
| Niacin Cholesterol Meta-Analysis | Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like particle that contains a unique apolipoprotein(a) [apo(a)] component covalently bound to apolipoprotein B-100. | 4 | Domański I (2026) | Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update. |
Source documents